Simultaneous integrated boost of biopsy proven, MRI defined dominant intra-prostatic lesions to 95 Gray with IMRT: Early results of a phase I NCI study

Radiation Oncology

Volumn 2, Issue 1, 2007, Pages

  Singh, Anurag K ^a   Guion, Peter ^b   Sears Crouse, Nancy ^b   Ullman, Karen ^b   Smith, Sharon ^b   Albert, Paul S ^b   Fichtinger, Gabor ^c   Choyke, Peter L ^b   Xu, Sheng ^d   Kruecker, Jochen ^d   Wood, Bradford J ^e   Krieger, Axel ^f   Ning, Holly ^b  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b NATIONAL CANCER INSTITUTE   (United States)

^c QUEEN S UNIVERSITY   (Canada)

^d PHILIPS RESEARCH LABORATORIES   (Netherlands)

^e NATIONAL INSTITUTES OF HEALTH   (United States)

^f Whiting School of Engineering   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; BIOPSY; CLINICAL TRIAL; FOLLOW UP; HEALTH CARE ORGANIZATION; HUMAN; INTENSITY MODULATED RADIATION THERAPY; MALE; METHODOLOGY; MULTICENTER STUDY; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL; PROSTATE TUMOR; QUESTIONNAIRE; RADIATION DOSE; UNITED STATES;

BIOPSY; FOLLOW-UP STUDIES; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; NATIONAL CANCER INSTITUTE (U.S.); PATIENT SELECTION; PROSTATIC NEOPLASMS; QUESTIONNAIRES; RADIOTHERAPY DOSAGE; RADIOTHERAPY, INTENSITY-MODULATED; UNITED STATES;

EID: 36148964828     PISSN: None     EISSN: 1748717X     Source Type: Journal    
DOI: 10.1186/1748-717X-2-36     Document Type: Article

References (21)

1. Jemal A Siegel R Ward E Murray T Xu J Thun MJ: Cancer statistics, 2007. CA: A cancer journal for clinicians 2007, 57(1):43-66. 17237035
2. Pollack A Zagars GK Starkschall G Antolak JA Lee JJ Huang E von Eschenbach AC Kuban DA Rosen I: Prostate cancer radiation dose response: results of the M. D. Anderson phase III randomized trial. Int J Radiat Oncol Biol Phys 2002, 53(5):1097-1105. 10.1016/S0360-3016(02)02829-8 12128107
3. Zietman AL DeSilvio ML Slater JD Rossi CJ Jr. Miller DW Adams JA Shipley WU Comparison of conventional-dose vs high-dose conformal radiation therapy in clinically localized adenocarcinoma of the prostate: A randomized controlled trial Jama 2005, 294(10):1233-1239. 10.1001/ jama.294.10.1233 16160131
4. Dearnaley DP Hall E Lawrence D Huddart RA Eeles R Nutting CM Gadd J Warrington A Bidmead M Horwich A: Phase III pilot study of dose escalation using conformal radiotherapy in prostate cancer: PSA control and side effects. Br J Cancer 2005, 92(3):488-498. 15685244
5. Peeters ST Heemsbergen WD Koper PC van Putten WL Slot A Dielwart MF Bonfrer JM Incrocci L Lebesque JV: Dose-response in radiotherapy for localized prostate cancer: Results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006, 24(13):1990-1996. 10.1200/JCO.2005.05.2530 16648499
6. van Tol-Geerdink JJ Stalmeier PF Pasker-de Jong PC Huizenga H van Lin EN Schimmel EC Leer JW van Daal WA: Systematic review of the effect of radiation dose on tumor control and morbidity in the treatment of prostate cancer by 3D-CRT. Int J Radiat Oncol Biol Phys 2006, 64(2):534-543. 10.1016/j.ijrobp.2005.07.974 16246497
7. Peeters ST Lebesque JV Heemsbergen WD van Putten WL Slot A Dielwart MF Koper PC: Localized volume effects for late rectal and anal toxicity after radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2006, 64(4):1151-1161. 10.1016/j.ijrobp.2005.10.002 16414208
8. Pollack A Hanlon A Horwitz EM Feigenberg S Uzzo RG Price RA: Radiation therapy dose escalation for prostate cancer: A rationale for IMRT. World J Urol 2003, 214:200-208. 10.1007/s00345-003-0356-x 12961097
9. Peeters ST Heemsbergen WD van Putten WL Slot A Tabak H Mens JW Lebesque JV Koper PC: Acute and late complications after radiotherapy for prostate cancer: Results of a multicenter randomized trial comparing 68 Gy to 78 Gy. Int J Radiat Oncol Biol Phys 2005, 61(4):1019-1034. 10.1016/ j.ijrobp.2004.07.715 15752881
10. Pouliot J Kim Y Lessard E Hsu IC Vigneron DB Kurhanewicz J: Inverse planning for HDR prostate brachytherapy used to boost dominant intraprostatic lesions defined by magnetic resonance spectroscopy imaging. Int J Radiat Oncol Biol Phys 2004, 59(4):1196-1207. 10.1016/ j.ijrobp.2004.02.055 15234056
11. DiBiase SJ Hosseinzadeh K Gullapalli RP Jacobs SC Naslund MJ Sklar GN Alexander RB Yu C: Magnetic resonance spectroscopic imaging-guided brachytherapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2002, 52(2):429-438. 10.1016/S0360-3016(01)02609-8 11872289
12. van Lin EN Futterer JJ Heijmink SW van der Vight LP Hoffmann AL van Kollenburg P Huisman HJ Scheenen TW Witjes JA Leer JW Barentsz JO Visser AG: IMRT boost dose planning on dominant intraprostaticGlesions: gold marker-based three-dimensional fusion of CT with dynamic contrast-enhanced and 1H-spectroscopic MRI. Int J Radiat Oncol Biol Phys 2006, 65(1):291-303. 10.1016/j.ijrobp.2005.12.046 16618584
13. Pickett B Vigneault E Kurhanewicz J Verhey L Roach M: Static field intensity modulation to treat a dominant intra-prostatic lesion to 90 Gy compared to seven field 3-dimensional radiotherapy. Int J Radiat Oncol Biol Phys 1999, 44(4):921-929. 10.1016/S0360-3016(98)00502-1 10386651
14. Xia P Pickett B Vigneault E Verhey LJ Roach M 3rd: Forward or inversely planned segmental multileaf collimator IMRT and sequential tomotherapy to treat multiple dominant intraprostatic lesions of prostate cancer to 90 Gy. Int J Radiat Oncol Biol Phys 2001, 51(1):244-254. 10.1016/ S0360-3016(01)01643-1 11516874
15. Susil RC Menard C Krieger A Coleman JA Camphausen K Choyke P Fichtinger G Whitcomb LL Coleman CN Atalar E: Transrectal prostate biopsy and fiducial marker placement in a standard 1.5T magnetic resonance imaging scanner. J Urol 2006, 175(1):113-120. 10.1016/S0022-5347(05)00065-0 16406885
16. Krieger A Susil RC Menard C Coleman JA Fichtinger G Atalar E Whitcomb LL: Design of a novel MRI compatible manipulator for image guided prostate interventions. IEEE Trans Biomed Eng 2005, 52(2):306-313. 10.1109/TBME.2004.840497 15709668
17. Kreucker J Xu S Glossop N Guion P Choyke P Singh AK Wood BJ: Fusion of real-time transrectal ultrasound with pre-acquired MRI for multi-modality prostate imaging. Proc of SPIE 2007,(8752):912-923.
18. Singh AK Kreucker J Xu S Glossop N Guion P Ullman K Choyke P Wood BJ: Clinical validation of real time ultrasound-MRI fusion guided prostate biopsy. BJU Int 2007, In Press
19. Wei JT Dunn RL Litwin MS Sandler HM Sanda MG: Development and validation of the expanded prostate cancer index composite (EPIC) for comprehensive assessment of health-related quality of life in men with prostate cancer. Urology 2000, 56(6):899-905. 10.1016/S0090-4295(00)00858-X 11113727
20. Anastasiadis AG Lichy MP Nagele U Kuczyk MA Merseburger AS Hennenlotter J Corvin S Sievert KD Claussen CD Stenzl A Schlemmer HP: MRI-guided biopsy of the prostate increases diagnostic performance in men with elevated or increasing PSA levels after previous negative TRUS biopsies. Eur Urol 2006, 50(4):738-48; discussion 748-9 10.1016/ j.eururo.2006.03.007 16630688
21. Singh AK Krieger A Latouf JB Guion P Grubb RL Albert PS Metzger G Ullman K Smith S Fichtinger G Ocak I Choyke P Ménard C Coleman J: Patient selection determines prostate cancer yield of dynamic contrast enhanced, MRI-guided trans-rectal biopsies in a closed 3 Tesla Scanner. BJU Int 2007. 17437438